Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
06:00am, Thursday, 05'th Mar 2026
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
04:01pm, Wednesday, 04'th Mar 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
09:06pm, Wednesday, 25'th Feb 2026
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Wednesday, 25'th Feb 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Xencor to Participate at Upcoming Investor Conferences
04:01pm, Monday, 23'rd Feb 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Analysts
01:52am, Friday, 13'th Feb 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports. One analyst has rated t
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving Average – What’s Next?
04:35am, Wednesday, 04'th Feb 2026
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $12.41 and traded a
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – What’s Next?
04:58am, Tuesday, 27'th Jan 2026
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $15.41 and traded as low as $12.50. X
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:26am, Monday, 19'th Jan 2026
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investme
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
08:01am, Thursday, 08'th Jan 2026
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
07:14am, Thursday, 01'st Jan 2026
XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D.
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
07:00am, Tuesday, 09'th Dec 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Xencor to Participate at Upcoming Investor Conferences
04:01pm, Monday, 10'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an
Y Intercept Hong Kong Ltd Purchases 46,140 Shares of Xencor, Inc. $XNCR
04:00am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd grew its position in shares of Xencor, Inc. (NASDAQ: XNCR) by 93.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 95,745 shares of t
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
06:36pm, Wednesday, 05'th Nov 2025
Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago.
